Phase 1 Study to Assess the Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients With Recurrent Epithelial Ovarian Cancer
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Success rate of autologous manufacturing
研究概览
简要总结
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer
详细描述
This is a Phase 1, open-label, single-center, pilot study of Innocell autologous cellular immunotherapy (i.e., Innocell vaccine) in patients with recurrent EOC.
The study is a 2-part design. For each participant, Part 1 will involve tissue procurement and confirmation of the ability to manufacture the Innocell vaccine, followed by Part 2 which is the treatment phase, involving Innocell administration to patients.
Part 1 - Tissue Procurement and Manufacturing of Innocell Vaccine
Participants will be screened to assure they fulfill the enrollment criteria. Screening must be performed within 30 days of administration of the Innocell regimen. Patients will undergo biopsy of the tumor. The team will target to harvest 1.0 gram or greater of tissue for the manufacturing process to produce 3 doses of Innocell and overage for testing. Upon successful manufacture and release testing, the Innocell vaccine series will be initiated.
Part 2 - Innocell Administration and Follow-up
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Open label Phase I trial with no masking
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years and female;
- •Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy and for whom single-agent therapy is appropriate as the next line of treatment;
- •Been treated with available standard-of-care therapy likely to convey clinical benefit (i.e., PARP inhibitors for women with germline BRCA mutation and in homologous recombination repair deficiency based on prior molecular testing or bevacizumab as appropriate);
- •Documented relapse or progression on or after the most recent line of therapy;
- •Patients must have at least 2 sites of measurable or detectable disease. The team will target to collect 1.0 gram of tumor tissue that can be removed and be available for manufacturing;
- •Eastern Collaborative Oncology Group (ECOG) performance status (PS) 0-2;
- •Recovery from clinically relevant toxicities to Grade 2 or less (except alopecia, peripheral neuropathy, and ototoxicity);
- •Adequate hematological, hepatic, and renal function obtained ≤ 28 days prior to planned initiation of vaccine series
- •Negative pregnancy test for women of childbearing potential and agree to practice a medically acceptable contraception regimen throughout the participation in the clinical trial; and,
- •Provide written informed consent for study participation.
排除标准
- •Positive clinical history of HIV, HCV, HBV, HTLV-1/2;
- •Diagnosis of immunodeficiency, either primary or acquired;
- •Active or prior history of autoimmune disease;
- •Note: The following conditions are permitted (i.e., not exclusionary) if the condition does not require immunosuppressive treatment:
- •Type 1 diabetes (if stable, well controlled, and not brittle); Vitiligo; Hypo- or hyperthyroid disease; or Autoimmune alopecia.
- •Treatment with systemic steroids or any other form of immunosuppressive therapy within 14 days prior to planned initiation of the Innocell vaccine; Note: Inhaled or topical steroids, including mouthwash, and adrenal replacement doses are permitted in the absence of active autoimmune disease.
- •Has any acute infection that requires specific therapy. Acute therapy must be completed at least 7 days prior to initiation of Innocell series;
- •Has received any live or attenuated vaccines against infectious diseases within 28 days of the planned vaccine initiation. Inactive vaccines, including SARS-CoV-2 vaccines authorized for use for active immunization to prevent COVID-19 are allowed and must be given in accordance with the prevailing immunization guidelines; or
- •Has received any other investigational agents within 4 weeks of planned vaccine initiation.
- •Hs received treatment with an approved systemic therapy within 3 weeks of planned vaccine initiation;
- •Prior malignancy, except those that were treated curatively and have not recurred within 5 years prior to study treatment; resected basal cell and squamous cell skin cancers;
- •History or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient to participate, in the opinion of the treating investigator; or
- •Inability of the subject to comply with study procedures and/or followup.
研究组 & 干预措施
Innocell an Autologous Cellular Immunotherapy
Innocell autologous immunotherapy will be administered with CpG 1018 adjuvant
干预措施: Innocell Autologous Cellular Immunotherapy (Biological)
结局指标
主要结局
Success rate of autologous manufacturing
时间窗: 2 months
Percent success rate to manufacture Innocell from autologous malignant tissue for patient administration
Safety assessed by treatment emergent adverse events
时间窗: From 1st dose of Innocell until 30 days post last dose
Proportion of subjects experiencing treatment emergent adverse events
次要结局
- Immune response to Innocell(Baseline to 30 days post last dose of Innocell)
- Immunogenicity of Innocell Vaccine(Baseline to 30 days post last dose of Innocell)
- Clinical response(Baseline to 30 days post last dose of Innocell, with long-term FU every 3 months x 1 year)